Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care
| Autor: | Henk M.W. Verheul, C. Willemien Menke-van der Houven van Oordt, Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Adriaan A. Lammertsma |
|---|---|
| Přispěvatelé: | Medical oncology, Clinical pharmacology and pharmacy, Radiology and nuclear medicine, CCA - Disease profiling |
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Biodistribution medicine.diagnostic_test business.industry medicine.medical_treatment Cancer General Medicine Single-photon emission computed tomography medicine.disease Molecular Imaging Targeted therapy Oncology Positron emission tomography Neoplasms Positron-Emission Tomography Humans Molecular Medicine Medicine Molecular Targeted Therapy Personalized medicine Precision Medicine Molecular imaging Nuclear medicine business Preclinical imaging |
| Zdroj: | Cellular Oncology, 38(1), 49-64. IOS Press Mammatas, L H, Verheul, H M W, Hendrikse, N H, Yaqub, M, Lammertsma, A A & van der Houven van Oordt, C W 2015, ' Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care ', Cellular Oncology, vol. 38, no. 1, pp. 49-64 . https://doi.org/10.1007/s13402-014-0194-4 |
| ISSN: | 2211-3428 |
| Popis: | Molecular imaging has been defined as the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans and other living systems. In oncology it enables to visualize (part of) the functional behaviour of tumour cells, in contrast to anatomical imaging that focuses on the size and location of malignant lesions. Available molecular imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET) and optical imaging. In PET, a radiotracer consisting of a positron emitting radionuclide attached to the biologically active molecule of interest is administrated to the patient. Several approaches have been undertaken to use PET for the improvement of personalized cancer care. For example, a variety of radiolabelled ligands have been investigated for intratumoural target identification and radiolabelled drugs have been developed for direct visualization of the biodistibution in vivo, including intratumoural therapy uptake. First indications of the clinical value of PET for target identification and response prediction in oncology have been reported. This new imaging approach is rapidly developing, but uniformity of scanning processes, standardized methods for outcome evaluation and implementation in daily clinical practice are still in progress. In this review we discuss the available literature on molecular imaging with PET for personalized targeted treatment strategies. Molecular imaging with radiolabelled targeted anticancer drugs has great potential for the improvement of personalized cancer care. The non-invasive quantification of drug accumulation in tumours and normal tissues provides understanding of the biodistribution in relation to therapeutic and toxic effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink